Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis

被引：9

作者：

van Kempen, Zoe L. E. ^{[1
]}

Hogenboom, Laura ^{[1
]}

Toorop, Alyssa A. ^{[1
]}

Steenhuis, Maurice ^{[2
]}

Stalman, Eileen W. ^{[3
]}

Kummer, Laura Y. L. ^{[2
,3
]}

van Dam, Koos P. J. ^{[3
]}

Bloem, Karien ^{[4
]}

ten Brinke, Anja ^{[2
]}

van Ham, S. Marieke ^{[2
,5
]}

Kuijpers, Taco W. ^{[6
]}

Wolbink, Gerrit J. ^{[2
,7
]}

Loeff, Floris C. ^{[4
]}

Wieske, Luuk ^{[3
,8
]}

Eftimov, Filip ^{[3
]}

Rispens, Theo ^{[2
]}

Strijbis, Eva M. M. ^{[1
]}

Killestein, Joep ^{[1
]}

机构：

[1] Vrije Univ, Dept Neurol, Amsterdam UMC, Amsterdam, Netherlands

[2] Amsterdam UMC, Sanquin Res & Landsteiner Lab, Dept Immunopathol, Amsterdam, Netherlands

[3] Univ Amsterdam, Dept Neurol & Neurophysiol, Locat AMC, Amsterdam UMC,Amsterdam Neurosci, Amsterdam, Netherlands

[4] Sanquin Diagnost Serv, Sanquin Lab, Amsterdam, Netherlands

[5] Univ Amsterdam, Swammerdam Inst Life Sci, Amsterdam, Netherlands

[6] Univ Amsterdam, Dept Pediat Immunol Rheumatol & Infect Dis, Locat AMC, Amsterdam UMC, Amsterdam, Netherlands

[7] Amsterdam Rheumatol & Immunol Ctr, Dept Rheumatol, Amsterdam, Netherlands

[8] St Antonius Hosp, Dept Clin Neurophysiol, Nieuwegein, Netherlands

来源：

ANNALS OF NEUROLOGY | 2023年 / 93卷 / 01期

关键词：

NATALIZUMAB; ANTIBODIES; MS;

D O I：

10.1002/ana.26534

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Ocrelizumab, an anti-CD20 monoclonal antibody, counteracts induction of humoral immune responses after severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccinations in patients with multiple sclerosis (MS). We aimed to assess if serum ocrelizumab concentration measured at the time of vaccination could predict the humoral response after SARS-CoV-2 vaccination. In 52 patients with MS, we found ocrelizumab concentration at the time of vaccination to be a good predictor for SARS-CoV-2 IgG anti-RBD titers after vaccination (comparable to B-cell count). As the course of ocrelizumab concentration may be predicted using pharmacokinetic models, this may be a superior biomarker to guide optimal timing for vaccinations in B-cell depleted patients with MS. ANN NEUROL 2022

引用

页码：103 / 108

页数：6

共 19 条

[1] Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study [J].

Bar-Or, Amit ;

Calkwood, Jonathan C. ;

Chognot, Cathy ;

Evershed, Joanna ;

Fox, Edward J. ;

Herman, Ann ;

Manfrini, Marianna ;

McNamara, John ;

Robertson, Derrick S. ;

Stokmaier, Daniela ;

Wendt, Jeanette K. ;

Winthrop, Kevin L. ;

Traboulsee, Anthony .

NEUROLOGY, 2020, 95 (14) :E1999-E2008

[2] Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod [J].

Cabeza, Virginia Palomares ;

Kummer, Laura Y. L. ;

Wieske, Luuk ;

Hagen, Ruth R. ;

Duurland, Mariel ;

Konijn, Veronique A. L. ;

van Dam, Koos P. J. ;

Stalman, Eileen W. ;

van de Sandt, Carolien E. ;

Boekel, Laura ;

Verstegen, Niels J. M. ;

Steenhuis, Maurice ;

Rispens, Theo ;

Tas, Sander W. ;

Wolbink, Gertjan ;

Killestein, Joep ;

Kuijpers, Taco W. ;

van Ham, S. Marieke ;

Eftimov, Filip ;

ten Brinke, Anja ;

van Kempen, Zoe L. E. .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (04)

[3] Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis [J].

Etemadifar, Masoud ;

Nouri, Hosein ;

Pitzalis, Maristella ;

Idda, Maria Laura ;

Salari, Mehri ;

Baratian, Mahshid ;

Mahdavi, Sepide ;

Abhari, Amir Parsa ;

Sedaghat, Nahad .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09) :986-994

[4] Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO [J].

Gibiansky, Ekaterina ;

Petry, Claire ;

Mercier, Francois ;

Gunther, Andreas ;

Herman, Ann ;

Kappos, Ludwig ;

Hauser, Stephen ;

Yamamoto, Yumi ;

Wang, Qing ;

Model, Fabian ;

Kletzl, Heidemarie .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) :2511-2520

[5] Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis [J].

Hauser, S. L. ;

Bar-Or, A. ;

Comi, G. ;

Giovannoni, G. ;

Hartung, H. -P. ;

Hemmer, B. ;

Lublin, F. ;

Montalban, X. ;

Rammohan, K. W. ;

Selmaj, K. ;

Traboulsee, A. ;

Wolinsky, J. S. ;

Arnold, D. L. ;

Klingelschmitt, G. ;

Masterman, D. ;

Fontoura, P. ;

Belachew, S. ;

Chin, P. ;

Mairon, N. ;

Garren, H. ;

Kappos, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) :221-234

[6] B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients [J].

Hogelin, Klara Asplund ;

Ruffin, Nicolas ;

Pin, Elisa ;

Hober, Sophia ;

Nilsson, Peter ;

Cucuzza, Chiara Starvaggi ;

Khademi, Mohsen ;

Olsson, Tomas ;

Piehl, Fredrik ;

Al Nimer, Faiez .

EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (11) :3317-3328

[7] Extended dosing of monoclonal antibodies in multiple sclerosis [J].

Kempen, Zoe L. E. van ;

Toorop, Alyssa A. ;

Sellebjerg, Finn ;

Giovannoni, Gavin ;

Killestein, Joep .

MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (13) :2001-2009

[8] Integrated immune dynamics define correlates of COVID-19 severity and antibody responses [J].

Koutsakos, Marios ;

Rowntree, Louise C. ;

Hensen, Luca ;

Chua, Brendon Y. ;

van de Sandt, Carolien E. ;

Habel, Jennifer R. ;

Zhang, Wuji ;

Jia, Xiaoxiao ;

Kedzierski, Lukasz ;

Ashhurst, Thomas M. ;

Putri, Givanna H. ;

Marsh-Wakefield, Felix ;

Read, Mark N. ;

Edwards, Davis N. ;

Clemens, E. Bridie ;

Wong, Chinn Yi ;

Mordant, Francesca L. ;

Juno, Jennifer A. ;

Amanat, Fatima ;

Audsley, Jennifer ;

Holmes, Natasha E. ;

Gordon, Claire L. ;

Smibert, Olivia C. ;

Trubiano, Jason A. ;

Hughes, Carly M. ;

Catton, Mike ;

Denholm, Justin T. ;

Tong, Steven Y. C. ;

Doolan, Denise L. ;

Kotsimbos, Tom C. ;

Jackson, David C. ;

Krammer, Florian ;

Godfrey, Dale, I ;

Chung, Amy W. ;

King, Nicholas J. C. ;

Lewin, Sharon R. ;

Wheatley, Adam K. ;

Kent, Stephen J. ;

Subbarao, Kanta ;

McMahon, James ;

Thevarajan, Irani ;

Thi H O Nguyen ;

Cheng, Allen C. ;

Kedzierska, Katherine .

CELL REPORTS MEDICINE, 2021, 2 (03)

[9] Why Therapeutic Drug Monitoring Is Needed for Monoclonal Antibodies and How Do We Implement This? [J].

Mould, D. R. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (04) :351-354

[10] Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody [J].

Rispens, Theo ;

van Leeuwen, Astrid ;

Vennegoor, Anke ;

Killestein, Joep ;

Aalberse, Rob C. ;

Wolbink, Gerrit J. ;

Aarden, Lucien A. .

ANALYTICAL BIOCHEMISTRY, 2011, 411 (02) :271-276

← 1 2 →